Schedule 13D ownership disclosure
Enliven Therapeutics Inc
COMMON STOCK · CUSIP: 29337E102
Event date: 2025-06-16
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLCReported CIK 0001055951
Shares: 7,918,163.00 · Class: 13.4%
- ORBIMED CAPITAL GP VII LLCReported CIK 0001760648
Shares: 7,663,349.00 · Class: 13.0%
- ORBIMED GENESIS GP LLCReported CIK 0001808744
Shares: 254,814.00 · Class: 0.4%
- ORBIMED CAPITAL LLCReported CIK 0001157524
Shares: 41,375.00 · Class: 0.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000616
- Form type
- SCHEDULE 13D/A
- Filer
- Enliven Therapeutics, Inc.
- CIK
- CIK 1672619
- Filed
- Jun 17, 2025
- Reporting period
- Jun 16, 2025
- Description
- Schedule 13D beneficial ownership